Wednesday 11/25 Insider Buying Report: CASI, CHMA

Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned dollars to make a purchase, is that they expect to make money.

Today we look at two noteworthy recent insider buys.

Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned dollars to make a purchase, is that they expect to make money.

Today we look at two noteworthy recent insider buys.

On Monday, CASI Pharmaceuticals' CEO, Wei-wu He, made a $488,239 buy of CASI, purchasing 227,471 shares at a cost of $2.15 each.

He was up about 38.4% on the buy at the high point of today's trading session, with CASI trading as high as $2.97 in trading on Wednesday.

CASI Pharmaceuticals, is trading up about 10.9% on the day Wednesday.

Before this latest buy, He bought CASI at 4 other times during the past twelve months, for a total investment of $10.5M at an average of $1.85 per share.

And also on Monday, Chief Executive Officer Raj Kannan purchased $480,492 worth of Chiasma, purchasing 120,000 shares at a cost of $4.00 a piece.

Before this latest buy, Kannan made one other buy in the past year, purchasing $42,000 shares at a cost of $4.20 each.

Chiasma is trading up about 9.8% on the day Wednesday.

Kannan was up about 12.6% on the buy at the high point of today's trading session, with CHMA trading as high as $4.51 in trading on Wednesday.